Effects of Insulin Resistance on the 12/15-Lipoxygenase Pathway in Visceral Fat
Project Number1F32DK079469-01
Contact PI/Project LeaderWILLIAMS, MICHAEL D
Awardee OrganizationUNIVERSITY OF VIRGINIA
Description
Abstract Text
DESCRIPTION (provided by applicant): Diabetes mellitus and obesity are increasing in prevalence, and are associated with increased risk for atherosclerotic cardiovascular disease. Activation of inflammatory processes in visceral fat is thought to contribute to the link between insulin resistance and atherosclerosis. The specific mechanisms involved in this inflammation, however, remain unclear. The hypothesis to be tested in the proposed research is that the 12/15-lipoxygenase (12/15-LO) pathway is important in mediating inflammatory changes in visceral fat, including cytokine production and macrophage infiltration, seen in states of insulin resistance. One specific aim is to evaluate the impact of varying degrees of insulin resistance on 12/15-LO pathway activation in visceral fat and in macrophages within visceral fat. Genetically insulin-resistant mice, which are heterozygous null at the insulin receptor and insulin receptor substrate-1 gene loci on the C57BL/6 background, will be fed along with wild-type C57BL/6 mice either a standard chow diet or a "western" diet which is high in saturated fat and precipitates or worsens insulin resistance. After either 15 or 30 weeks of feeding, visceral adipocytes and macrophages from visceral fat will be harvested, inflammatory gene expression will be measured using quantitative real-time PCR, and cytokine proteins will be studied by immunoassay. Trafficking of macrophages into visceral fat will be quantitated by fluorescence-activated cell sorting and immunohistochemistry. It is expected that more severely insulin-resistant animals will demonstrate higher levels of inflammatory activation. A second aim is to determine the importance of 12/15-LO activity in the inflammatory gene expression, cytokine production, and macrophage trafficking associated with insulin resistance. Mice which either have a deletion at the 12/15-LO gene locus or are transgenic for 12/15-LO, both on the C57BL/6 background, will be fed along with wild-type C57BL/6 mice either chow or the western diet. The techniques outlined above will be used to measure markers of inflammation. It is expected that visceral fat inflammatory activation in response to insulin resistance will vary directly with the genetically predetermined activity of 12/15-LO. This research has potential to identify the currently unclear inflammatory processes activated by insulin resistance in fat, and therefore facilitate specific targeted therapy to reduce development of atherosclerosis in the setting of diabetes and pre-diabetes. The ability to apply such measures to the population at large could greatly impact the currently increasing incidence of coronary events and cardiovascular mortality.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
065391526
UEI
JJG6HU8PA4S5
Project Start Date
01-July-2007
Project End Date
30-June-2008
Budget Start Date
01-July-2007
Budget End Date
30-June-2008
Project Funding Information for 2007
Total Funding
$55,292
Direct Costs
$55,292
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Diabetes and Digestive and Kidney Diseases
$55,292
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1F32DK079469-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1F32DK079469-01
Patents
No Patents information available for 1F32DK079469-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1F32DK079469-01
Clinical Studies
No Clinical Studies information available for 1F32DK079469-01
News and More
Related News Releases
No news release information available for 1F32DK079469-01
History
No Historical information available for 1F32DK079469-01
Similar Projects
No Similar Projects information available for 1F32DK079469-01